EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes

and Acute Coronary Syndrome

EXAMINE: CV End Points

SAVOR-TIMI 53 Study: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone

or Added to Other Diabetes Medications?

SAVOR-TIMI 53: CV End Points

Safety End Points

Clinical Implications

CV Events With Rosiglitazone

Global Cost of Diabetes

Insights From SAVOR-TIMI 53

DPP-4 Inhibitors

Hypoglycemia: Impact on Quality of Life

Take-Home Messages

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)